EN KR
Linkedin Facebook

SaaS

DR HIT-SCR AI-enabled Drug Discovery Solution for Drug Repurposing

"DR-Screening" is a solution that supports drug repurposing by quickly discovering new medical uses in selected libraries of 17,000 existing drugs. The libraries include a variety of drugs that are FDA-approved or in preclinical/clinical trials. A proven platform with up to 23.3% hit rates across in various therapeutic areas and multiple protein families, including kinase, GPCR, and nuclear receptors. Furthermore, it is validated to cover various target and disease areas.

"DR-Screening" is a solution that supports drug repurposing by quickly discovering new medical uses in selected libraries of 17,000 existing drugs. The libraries include a variety of drugs that are FDA-approved or in preclinical/clinical trials. A proven platform with up to 23.3% hit rates across in various therapeutic areas and multiple protein families, including kinase, GPCR, and nuclear receptors. Furthermore, it is validated to cover various target and disease areas.
SCROLL DOWN

Solution

Are you considering an ever greening strategy to extend the patent life of your drugs?

STB can help extend the patent rights by adding new indications based on accumulated experiences.

Need to quickly add new pipelines Or find  treatment for new pandemic diseases in the fastest way?

STB can support it with drug repurposing with selected DR libraries and integrated technology.

looking for HIT compounds that meet the safety and physicochemical properties?

STB can help reduce development time and costs by finding new uses of existing or investigational drugs.

Workflow

DR Library DR Library

ADR Library (Drug repurposing)

  • Start screening new HITs from extensive libraries of up to 17,000 compounds.

I/O: Target protein info. & Ref. drug info. (if available)

Deep Learning Screening Deep Learning Screening

BDeep Learning Screening

  • After preliminary screening based on physicochemical properties, AI-3D docking of target-compound is conducted.
  • Next, various conformers and binding poses for the compounds are generated and then prioritized by CNN scoring.
False Positive filtering False Positive filtering

CFalse Positive Filtering

  • The best-pose is selected based on the binding energy of Cpds and false positives are filtered out through auto-MD simulation.
  • The Cpds are then scored based on various factors for each best-poses.

Output: List of 200 Cpds with false positives filtered 

Technical Performance Technical Performance

DTechnical Performance

  • The final HIT candidates are re-ranked with our own scoring functions, providing a list of  ~200 top-ranked compounds that are ready-to-purchase without any synthesis steps.

Input: The screening score of 200 Cpds

Application

  • Discovering new targets and indications of known drugs
  • Extending patent rights and pipelines by adding new indications of existing drugs
  • Development of me-too drugs based on existing drugs
  • (On request) Subsequent development is available based on DR drugs in the early stage discovered in-house
References:
  • “Protein-ligand scoring with convolutional neural networks.” JCIM 57.4 (2017): 942-957.
  • Syntekabio’s Hit to Preclinical Candidate on Cloud Computing. BioPharma Trend Vol4. 2023.
  • How Syntekabio’s Supercomputing Enables AI-driven Drug Discovery. BioPharma Trend Vol3. 2023

Auto-Hit Discovery by DeepMatcher®-Hit

The DeepMatcher® platform solves two key challenges in early-stage drug discovery: speed and precision.

In the new drug development market, the need for a new approach has emerged as drug discovery through the traditional methods has reached a saturation point. Accordingly, AI-based drug discovery platforms have been attempted. Syntekabio offers innovative services that prioritize convenience and cost-effectiveness in discovering new drug candidates.
Syntekabio’s DeepMatcher® platform resolved two key issues of the early-stage drug discovery: speed and precision. The hit discovery and lead optimization (lead-opt) process, which normally takes at least two, three years in a classical drug R&D setting, now takes only a few months with the help of AI technology.

Essential Key-challenges for Auto Hit Discovery

Flow diagram of Hit discovery by DeepMatcher® Compounds are prescreened through three steps before being docked in a pocket of the target. Once the optimal pose is selected, the MD simulation is finally performed in a total of five steps.

Essential Key-challenges for Auto Hit Discovery Essential Key-challenges for Auto Hit Discovery
  • 1Purchasable Chemical Library (1 Billion)
  • 2Physical-3D Docking (1 Million)
  • 33D-CNN Binding Mode Tuning (1k)
  • 4MD Simulation (1k) for Fine-tune

Purchasable Chemical Library

Syntekabio launched STB CLOUD in late 2022, a suite of cloud-based proprietary platforms, to meet the unmet needs of these cost-conscious innovators seeking reliable yet affordable new drug candidate discovery services. STB CLOUD screens 1 billion purchasable compounds based on unique featurization method for 3D information-based data and 1 million potential candidate compounds

Physical-3D Docking

One million chemicals selected from a library of 1 billion compounds was docked into target 3D structure using command line interface (CLI) based in-house structure manipulation package.

Figure2

Figure2. Chemicallibrary

Figure3

Figure3. Methods for centroidal atom vector-based fast protein-ligand docking. After docking, three atom-vector based rotations along the core ring. It rotates while moving 1000 times in each revolution and then, generates a protein-ligand interaction (PLI) score

3D-CNN for Binding Tuning

The diagram below shows the interaction between a protein and a ligand in the pocket as a grid box, a 3D-CNN based intermediate stage of repeated max pooling and 3D convolution, generating feature maps, and representing bonds. Here, the starting grid box (48) and kernel size (3*3*3) are used. The density function is based on the geometry of adjacent bonds of two atoms. Therefore, the sum of bonds is defined as binding affinity.

3D-CNN for Binding Tuning 3D-CNN for Binding Tuning
Figure5. Auto-MD simulation

Figure5. Auto-MD simulation

Auto-MD Simulation

Syntekabio's fully automated MD simulation algorithm performs molecular dynamics simulations (10 ns) in explicit water box for 1,000 protein-ligand complexes.

The diagram shows an example of running continuously from a dead step during 1,000 MD simulations. If one runs 1000 MD simulations at once, a large number of simulations may crash and die in certain cases. However, in the automated environment, it proceeds by saving the checkpoint and resume from the saved point.

Figure 6.  Comparison of AI-hit positive andnegative predictions with known Molecules.

Figure 6. Comparison of AI-hit positive andnegative
predictions with known Molecules.

Key-Residue Analysis

The known molecules and the predicted molecules with EGFR protein were compared to see if the functional (Hinge, DFG) and conformational keys (G-loop, M766 in c-Helix) were well matched. In the case of positive prediction, the functional and conformational keys were well matched, whereas in case of negative, there were few matched residues. (Red: strong binding, Blue: weak binding)

Hit validation

CLK2, also known as CDC-like kinase 2, is a protein kinase that plays a role in the regulation of pre-mRNA splicing. Presented 89 candidate compounds using Deepmatcher®-Hit as a result of structure analysis using tanimoto coefficient with KNN algorithm. a) It was confirmed that 89 compounds were divided into 7 groups. b) Purchasable compounds were biochemically confirmed their inhibition activities. Three compounds of 74 purchased candidates (yellow circles) inhibited enzyme activity of CLK2 more than 50%. c) The growth inhibitory effect of each cancer cell by treatment with STB-C070, STB-C070-D157 and reference compounds were analyzed using WST-1 assay. GI50 was calculated from the 8-point dose-response curves by triplicate test.

a) DeepMatcher® Result analysis

a) DeepMatcher® Result analysis

b) Biochemical assay result of AI-hits

b) Biochemical assay result of AI-hits

c) Cell-based assay result of AI-hits

c) Cell-based assay result of AI-hits

send us your inquiry

SUBMIT
SUBMIT